BioTime Inc (BTX)

3.66
0.14 3.70
AMEX : Health Care
Prev Close 3.80
Open 3.72
Day Low/High 3.61 / 3.76
52 Wk Low/High 2.00 / 4.10
Volume 162.97K
Avg Volume 297.00K
Exchange AMEX
Shares Outstanding 103.39M
Market Cap 395.99M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioTime To Present At Two Upcoming Investor Conferences

BioTime To Present At Two Upcoming Investor Conferences

BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the following investor conferences: ...

BioTime Announces Issuance Of 31 New Patents To Strengthen Its Patent Portfolio In Regenerative Medicine

BioTime Announces Issuance Of 31 New Patents To Strengthen Its Patent Portfolio In Regenerative Medicine

BioTime, Inc. (NYSE MKT:BTX) today announced the issuance of 31 new patents between July 3, 2015 and August 3, 2016 that are owned by or licensed to BioTime, or its family of companies.

BioTime, Inc. Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the second quarter ended June 30, 2016 and provided a...

BioTime, Inc. To Report Second Quarter Results On August 9, 2016

BioTime, Inc. To Report Second Quarter Results On August 9, 2016

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will release second quarter financial and operating results on Tuesday,...

BioTime, Inc. Announces Full Exercise And Closing Of Underwriters' Over-Allotment Option

BioTime, Inc. Announces Full Exercise And Closing Of Underwriters' Over-Allotment Option

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced that the underwriters of BioTime, Inc.

BioTime Presents Online Resource For Applying Artificial Intelligence To Stem Cell Biology At Mensa 2016 Annual Gathering

BioTime Presents Online Resource For Applying Artificial Intelligence To Stem Cell Biology At Mensa 2016 Annual Gathering

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that Co-CEO Dr.

BioTime, Inc. Announces Closing Of Public Offering Of Common Stock

BioTime, Inc. Announces Closing Of Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the closing of its previously announced...

BioTime, Inc. Announces Pricing Of Public Offering Of Common Stock

BioTime, Inc. Announces Pricing Of Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the pricing of an underwritten public...

BioTime, Inc. Announces Proposed Public Offering Of Common Stock

BioTime, Inc. Announces Proposed Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced its intent to offer to sell shares of its...

BioTime's Subsidiary Cell Cure Neurosciences Receives DSMB Approval To Start Second Patient Cohort In Clinical Trial For Dry-AMD

BioTime's Subsidiary Cell Cure Neurosciences Receives DSMB Approval To Start Second Patient Cohort In Clinical Trial For Dry-AMD

BioTime, Inc. (NYSE MKT and TASE: BTX) and Cell Cure Neurosciences Ltd.

BioTime Announces $2.2 Million Grant For Further Development Of Dry-AMD Program

BioTime Announces $2.2 Million Grant For Further Development Of Dry-AMD Program

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, and its subsidiary Cell Cure Neurosciences Ltd.

BioTime To Present At The Jefferies 2016 Global Healthcare Conference

BioTime To Present At The Jefferies 2016 Global Healthcare Conference

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the company will present at the Jefferies 2016 Global Healthcare...

BioTime To Present At Two Upcoming Investor Conferences

BioTime To Present At Two Upcoming Investor Conferences

BioTime, Inc. (NYSE MKT and TASE: BTX) announced that Co-Chief Executive Officer Michael D.

BioTime, Inc. Reports First Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. Reports First Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the first quarter ended March 31, 2016 and...

BioTime Co-CEO Dr. Michael West Presents At Biomedical Innovation For Healthy Longevity, International Conference

BioTime Co-CEO Dr. Michael West Presents At Biomedical Innovation For Healthy Longevity, International Conference

BioTime, Inc. (NYSE MKT:BTX) announced that Co-Chief Executive Officer Michael D.

LifeMap Solutions Launches Full-Service Mobile Health App Design & Development To Meet The Needs Of Medical, Research, And Commercial Partners

LifeMap Solutions Launches Full-Service Mobile Health App Design & Development To Meet The Needs Of Medical, Research, And Commercial Partners

LifeMap Solutions, the digital health subsidiary of BioTime, Inc. (NYSE MKT: BTX) and co-developer of ResearchKit-enabled app Asthma Health, today announced a new service to develop custom smartphone apps and research...

BioTime Co-CEO Dr. Michael West To Present At Stem Cells In Drug Discovery 2016 In Cambridge, UK

BioTime Co-CEO Dr. Michael West To Present At Stem Cells In Drug Discovery 2016 In Cambridge, UK

BioTime, Inc. (NYSE MKT: BTX) today announced that Co-Chief Executive Officer Michael D.

5 Hated Stocks Poised to Turn Around on Earnings

5 Hated Stocks Poised to Turn Around on Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

BioTime, Inc. To Host Conference Call To Update Investors On Recent Accomplishments And Corporate Objectives For 2016

BioTime, Inc. To Host Conference Call To Update Investors On Recent Accomplishments And Corporate Objectives For 2016

BioTime, Inc. (NYSE MKT:BTX) today announced that it will host a conference call on Thursday, March 31, to update investors on the Company's recent accomplishments and objectives for the remainder of 2016.

Asterias Biotherapeutics Appoints Stephen L. Cartt President And Chief Executive Officer

Asterias Biotherapeutics Appoints Stephen L. Cartt President And Chief Executive Officer

-- Don M. Bailey Appointed to Board of Directors and Named Chairman --

BioTime Subsidiary Asterias Biotherapeutics Reports The Successful End-of-Phase II FDA Meeting For Immunotherapy In Acute Myeloid Leukemia

BioTime Subsidiary Asterias Biotherapeutics Reports The Successful End-of-Phase II FDA Meeting For Immunotherapy In Acute Myeloid Leukemia

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its subsidiary, Asterias Biotherapeutics ("Asterias"), has successfully...

BioTime And Asterias Sign Share Transfer Agreement And Cross-License Agreement For Pluripotent Stem Cell Related Patents

BioTime And Asterias Sign Share Transfer Agreement And Cross-License Agreement For Pluripotent Stem Cell Related Patents

Asterias Biotherapeutics, Inc. (NYSE MKT:AST) and BioTime, Inc.

BioTime, Inc. To Present At Three Investor Conferences In February

BioTime, Inc. To Present At Three Investor Conferences In February

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, announced today that it will present at the following three investor conferences in February:...

Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018

Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018

BioTime, Inc. (NYSE MKT and TASE: BTX) announced today that pursuant to Section 6.

BioTime Completes Distribution Of Approximately 4.75 Million Shares Of OncoCyte Corporation Common Stock

BioTime Completes Distribution Of Approximately 4.75 Million Shares Of OncoCyte Corporation Common Stock

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, has completed its previously announced distribution of approximately 4.

BioTime Announces

BioTime Announces "When-Issued" Trading Of Subsidiary OncoCyte Corporation In Connection With Planned Distribution

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the common stock of its subsidiary OncoCyte Corporation ("OncoCyte") will...

OncoCyte Appoints Dr. Andrew J. Last To Its Board Of Directors

OncoCyte Appoints Dr. Andrew J. Last To Its Board Of Directors

OncoCyte Corporation ("OncoCyte"), a company focused on non-invasive cancer diagnostics, announced the appointment of Dr.

BioTime Co-Chief Executive Officer Michael D. West, PhD To Deliver Keynote Speech At The 2015 World Stem Cell Summit

BioTime Co-Chief Executive Officer Michael D. West, PhD To Deliver Keynote Speech At The 2015 World Stem Cell Summit

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its co-Chief Executive Officer Michael D.